



Accredited by
Joint Commission International

Indraprastha Medical Corporation Limited

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi - 110 076. (INDIA)

Corporate Identity Number : L24232DL 1988PLC030958

Phone : 26925801, 26925858 Fax : 91-11-26825601

E-mail : asinghal@apollohospitals.com Website : apollohospdelhi.com



A. K. SINGHAL

Vice President
Cum Company Secretary

Ref: IMCL/CS/BM/2018

9th May, 2018

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Re: Outcome of the Board Meeting held on 9th May, 2018

Dear Sir,

Pursuant to provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) we wish to inform you that the Board of Directors at its meeting held today i.e. on 9th May, 2018 have approved:

1. The audited financial results of the company for the quarter and financial year ended 31st March 2018.

Please find enclosed audited financial results for the quarter and financial year ended 31st March, 2018 along with a copy of the unmodified Audit Report by the Statutory Auditors of the Company.

In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, a declaration by CFO confirming that the Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year ended 31st March 2018, is also enclosed.

In terms of Regulation 47 of the Listing Regulation, the extracts of the financial results, in the prescribed format shall be published within 48 hours of conclusion of the meeting i.e. on or before 11th May, 2018 in all editions of Financial Express (English) and Delhi edition of Jansatta (Hindi Daily).

The full format of the financial results for the quarter/ year ended 31st March 2018 shall be available on the website of the Stock exchange where equity share of the Company are listed i.e. www.nseindian.com and www.bseindia.com and on Company's website www.apollohospdelhi.com.





Accredited by
Joint Commission International

A. K. SINGHAL

Vice President
Cum Company Secretary

Indraprastha Medical Corporation Limited

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi - 110 076. (INDIA)

Corporate Identity Number : L24232DL 1988PLC030958

Phone : 26925801, 26925858 Fax : 91-11-26825601

E-mail : asinghal@apollohospitals.com Website : apollohospdelhi.com



2. Recommendation of Dividend

Pursuant to Regulation 30 & 43 of the Listing Regulations, we wish to inform you that the Board of Directors of the Company, recommended the payment of dividend @ 15% i.e. Rs. 1.50 per share for the financial year 2017-18.

Dividend if approved by the shareholders will be paid on or before 30th October, 2018.

The Board meeting commenced at 3.00 p.m. and ended at 6.35 p.m.

This is for your information and record.

Thanking You,

Sincerely Yours,

A.K.SINGHAL

Encl. As above

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Indraprastha Medical Corporation Limited

We have audited the accompanying statement of financial results of **Indraprastha Medical Corporation Limited** ("the Company") for the quarter and year ended March 31, 2018 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated July 5, 2016. Attention is drawn to the fact that the figures for the quarter ended March 31, 2018 as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to an audit. This Statement has been prepared on the basis of the reviewed quarterly financial results up to the end of the third quarter, the audited annual financial statements as at and for the year ended March 31, 2018, and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which is the responsibility of the Company's management and have been approved by the Board of Directors of the Company.

Our responsibility is to express an opinion on the Statement based on our review of financial results for the nine months period ended December 31, 2017, which was prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', issued pursuant to Companies (Indian Accounting Standards) Rules, 2015 as specified in Section 133 of the Companies Act, 2013 read with SEBI Circular dated July 5, 2016 and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended March 31, 2018; and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

Based on our audit conducted as above, in our opinion and to the best of our information and according to the explanations given to us, the accompanying Statement:

- (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016 in this regard; and
- (ii) give a true and fair view of the net profit (financial performance including other comprehensive income) and other financial information for the quarter and year ended March 31, 2018.



The comparative financial information and financial statements of the Company for the corresponding quarter March 31, 2017 and corresponding year ended March 31, 2017 included in the Statement, were audited by the predecessor auditors who expressed an unmodified opinion on those financial information and financial statements on May 26, 2017. Our opinion is not modified in respect of this matter.

For **S.N. Dhawan & Co LLP**
(Formerly *S. N. Dhawan & Co.*)
Chartered Accountants
Firm Registration No.: 000050N/N500045

Rajeev K Saxena
Partner
Membership No.: **077974**



New Delhi, May 09, 2018

Statement of Audited Financial Results for the Quarter and Year ended 31st March, 2018

Amount (Rs. in Lacs)

S. No.	Particulars	Quarter ended			Year ended	
		31.03.2018 (Audited)	31.12.2017 (Unaudited)	31.03.2017 (Audited)	31.03.2018 (Audited)	31.03.2017 (Audited)
1	Revenue from operations	18905.12	18408.57	18739.99	74835.58	76571.62
2	Other Income	9.27	132.13	10.02	159.93	45.71
3	Total income	18914.39	18540.70	18750.01	74995.51	76617.33
4	Expenses					
	a) Cost of material consumed	3405.58	3359.90	3729.65	13984.14	15239.53
	b) Purchase of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	d) Employee benefits expense	5058.15	4889.17	4866.36	19401.37	19025.71
	e) Consultation fee paid to Doctors	4643.75	4652.75	4612.32	19025.68	19145.51
	f) Finance cost	207.57	239.89	221.75	889.94	790.54
	g) Depreciation and amortisation expense	758.87	773.14	826.21	3068.18	3053.21
	h) Other expenses	3818.06	3789.83	3748.76	15225.68	15281.08
	Total expenses	17891.98	17704.68	18005.05	71594.99	72535.58
5	Profit before exceptional items and tax	1022.41	836.02	744.96	3400.52	4081.75
6	Exceptional items	-	-	-	-	-
7	Profit before tax (PBT)	1022.41	836.02	744.96	3400.52	4081.75
8	Tax expense					
	Current tax	609.13	174.60	471.81	1393.07	1854.10
	Deferred tax	(144.93)	109.71	(194.85)	(102.88)	(396.88)
9	Profit for the period after tax (PAT)	558.21	551.71	468.00	2110.33	2624.53
10	Other comprehensive income					
	a). (i) Items that will not be reclassified to profit or loss	(39.28)	45.00	65.56	37.27	106.14
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	13.47	(15.57)	(22.69)	(13.02)	(36.73)
	Total other comprehensive income, Net of tax expenses	(25.81)	29.43	42.87	24.25	69.41
11	Total comprehensive income for the period	532.40	581.14	510.87	2134.58	2693.94
12	Paid-up equity share capital (Face value Rs. 10/- each)	9167.30	9167.30	9167.30	9167.30	9167.30
13	Earnings per share Basic and Diluted (Rs.)	0.61	0.60	0.51	2.30	2.86

ABaypai



Notes:

1. Statement of Assets and Liabilities		As at 31 st March 2018	As at 31 st March 2017
Particulars			
ASSETS			
1 Non-current assets			
(a) Property, Plant and Equipment		29277.22	29389.31
(b) Intangible Assets		118.95	183.67
(c) Financial Assets		276.94	278.54
(d) Other non-current Assets		335.64	198.84
Total of Non-current assets		30008.75	30050.36
2 Current assets			
(a) Inventories		912.41	994.87
(b) Financial Assets			
(i) Trade receivables		8745.52	9831.12
(ii) Cash and cash equivalents		251.59	193.76
(iii) Bank Balances other than (ii) above		542.55	505.04
(iv) Loans		39.94	36.64
(v) Others		659.49	1087.08
(c) Current Tax Assets (Net)		776.48	886.36
(d) Other current assets		1683.14	2259.14
Total of Current assets		13611.12	15794.01
TOTAL OF ASSETS		43619.87	45844.37
EQUITY AND LIABILITIES			
1 Equity			
(a) Equity Share capital		9167.30	9167.30
(b) Other Equity		14064.01	13915.47
Total of Equity		23231.31	23082.77
Liabilities			
2 Non-current liabilities			
(a) Financial Liabilities			
(i) Borrowings		2100.00	-
(ii) Other Financial liabilities		276.00	251.39
(b) Provisions		873.04	870.16
(c) Deferred tax liabilities (Net)		2975.98	3065.83
Total of Non-current liabilities		6225.02	4187.38
3 Current liabilities			
(a) Financial Liabilities			
(i) Borrowings		3855.75	6481.01
(ii) Trade payables		7156.49	9620.87
(iii) Other financial liabilities		764.79	326.08
(b) Other current liabilities		1649.25	1783.66
(c) Provisions		737.26	362.60
Total of Current liabilities		14163.54	18574.22
TOTAL OF EQUITY AND LIABILITIES		43619.87	45844.37

ABaypan



2. The Company adopted Indian Accounting Standards ("Ind AS") from April 1,2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles stated there in, prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS.
3. The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 9th May, 2018.
4. The Board of Directors have recommended a dividend @ 15% (Rs. 1.50/- per share) for the financial year 2017-18
5. The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
6. Previous year figures have been regrouped / rearranged wherever necessary. The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial years.

Place : New Delhi
Date : 9th May, 2018


Ashok Bajpai
Managing Director



Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals, New Delhi - A Joint Sector Venture of Govt. of Delhi)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi-110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phones : 91-11-26925858, 26925801, Fax : 91-11-26823629

E-mail : imcl@apollohospitals.com, Website : apollohospdelhi.com

Ref: IMCL/CS/BM/2018

9th May, 2018

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Re: Declaration in terms of regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015


Dear Sir,

In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we confirm that the Statutory Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year 2017-18.

Thanking you,

Yours faithfully,

For Indraprastha Medical Corporation Limited



C. P. Tyagi
Chief Financial Officer